PMID- 32940858
OWN - NLM
STAT- MEDLINE
DCOM- 20211101
LR  - 20211101
IS  - 1776-260X (Electronic)
IS  - 1776-2596 (Linking)
VI  - 15
IP  - 5
DP  - 2020 Oct
TI  - Gilteritinib: A Review in Relapsed or Refractory FLT3-Mutated Acute Myeloid 
      Leukaemia.
PG  - 681-689
LID - 10.1007/s11523-020-00749-3 [doi]
AB  - Gilteritinib (Xospata((R))), a next-generation tyrosine kinase inhibitor (TKI), is 
      approved in several countries/regions worldwide for the treatment of relapsed or 
      refractory acute myeloid leukaemia (AML) in adults with FMS-like tyrosine kinase 
      3 (FLT3) mutations. In this patient population, oral gilteritinib significantly 
      improved overall survival (OS) and the response rate for complete remission with 
      full or partial haematological recovery compared with salvage chemotherapy in the 
      phase III ADMIRAL trial. In an integrated safety analysis of patients with 
      relapsed or refractory AML, the most commonly reported grade >/= 3 
      treatment-related adverse events (AEs) in gilteritinib recipients included 
      anaemia, febrile neutropenia and thrombocytopenia. Clinically relevant AEs of 
      special interest (AESIs) with gilteritinib therapy included differentiation 
      syndrome, posterior reversible encephalopathy syndrome, QT interval prolongation 
      and pancreatitis. AEs, including AESIs, were generally manageable with dose 
      reduction, interruption or discontinuation. All patients of reproductive 
      potential should use contraception during gilteritinib treatment due to the risk 
      of embryo-foetal toxicity. Given its convenient oral regimen, along with the poor 
      prognosis and paucity of treatment options for adults with relapsed or refractory 
      FLT3-mutated AML, gilteritinib represents a valuable first-line targeted 
      monotherapy in these patients.
FAU - Kang, Connie
AU  - Kang C
AD  - Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. 
      demail@springer.com.
FAU - Blair, Hannah A
AU  - Blair HA
AD  - Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - France
TA  - Target Oncol
JT  - Targeted oncology
JID - 101270595
RN  - 0 (Aniline Compounds)
RN  - 0 (Pyrazines)
RN  - 0 (gilteritinib)
SB  - IM
MH  - Aniline Compounds/pharmacology/*therapeutic use
MH  - Female
MH  - Humans
MH  - Leukemia, Myeloid, Acute/*drug therapy/pathology
MH  - Male
MH  - Middle Aged
MH  - Pyrazines/pharmacology/*therapeutic use
EDAT- 2020/09/18 06:00
MHDA- 2021/11/03 06:00
CRDT- 2020/09/17 12:17
PHST- 2020/09/18 06:00 [pubmed]
PHST- 2021/11/03 06:00 [medline]
PHST- 2020/09/17 12:17 [entrez]
AID - 10.1007/s11523-020-00749-3 [pii]
AID - 10.1007/s11523-020-00749-3 [doi]
PST - ppublish
SO  - Target Oncol. 2020 Oct;15(5):681-689. doi: 10.1007/s11523-020-00749-3.